利用蛋白质组学推动精准糖尿病医学
本文为叙述性综述,评估亲和法蛋白质组学在大规模临床研究中的应用及基于质谱的血浆蛋白质组学的优势与可行性,探讨蛋白质组学用于识别2型糖尿病亚型分型的预测性蛋白组合及构建预防、诊断、预后和治疗策略的临床预测模型,并讨论血浆与组织蛋白质组学及其与基因组学整合(蛋白质基因组学)在识别2型糖尿病亚型内和亚型间病因学中的重要性。
要点
- 亲和法蛋白质组学已广泛用于大规模临床研究,基于质谱的血浆蛋白质组学显示出应用前景。
- 蛋白质组学可用于识别2型糖尿病亚型分型的预测性蛋白组合并构建临床预测模型。
- 血浆与组织蛋白质组学及其与基因组学整合有助于识别2型糖尿病亚型内和亚型间病因学。
核心结论
- 蛋白质组学在精准糖尿病医学中具有改善预防、诊断、预后预测和治疗策略的潜力。
- 作者呼吁推进蛋白质组学技术、基准测试其性能并实现跨站点标准化,强调数据共享和在大规模队列研究中纳入不同 ancestry 人群。
研究设计与样本
- 叙述性综述,评估广泛采用的亲和法蛋白质组学在大规模临床研究中的应用,并呈现基于质谱的血浆蛋白质组学的益处与可行性证据。
主要发现
- 创新蛋白质组学技术与基因组学一起在精准肿瘤医学中已证明有效,并在糖尿病研究中显示出转化前景。
- 蛋白质组学可用于识别2型糖尿病亚型分型的预测性蛋白组合,并开发用于预防、诊断、预后和治疗策略的临床预测模型。
- 血浆和组织蛋白质组学及其与基因组学整合(蛋白质基因组学)有助于识别2型糖尿病亚型内和亚型间病因学。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Precision diabetes medicine (PDM) aims to reduce errors in prevention programmes, diagnosis thresholds, prognosis prediction and treatment strategies. However, its advancement and implementation are difficult due to the heterogeneity of complex molecular processes and environmental exposures that influence an individual's disease trajectory. To address this challenge, it is imperative to develop robust screening methods for all areas of PDM. Innovative proteomic technologies, alongside genomics, have proven effective in precision cancer medicine and are showing promise in diabetes research for potential translation. This narrative review highlights how proteomics is well-positioned to help improve PDM. Specifically, a critical assessment of widely adopted affinity-based proteomic technologies in large-scale clinical studies and evidence of the benefits and feasibility of using MS-based plasma proteomics is presented. We also present a case for the use of proteomics to identify predictive protein panels for type 2 diabetes subtyping and the development of clinical prediction models for prevention, diagnosis, prognosis and treatment strategies. Lastly, we discuss the importance of plasma and tissue proteomics and its integration with genomics (proteogenomics) for identifying unique type 2 diabetes intra- and inter-subtype aetiology. We conclude with a call for action formed on advancing proteomics technologies, benchmarking their performance and standardisation across sites, with an emphasis on data sharing and the inclusion of diverse ancestries in large cohort studies. These efforts should foster collaboration with key stakeholders and align with ongoing academic programmes such as the Precision Medicine in Diabetes Initiative consortium.
引用
- Kurgan N, Kjærgaard Larsen J, Deshmukh AS, et al. Harnessing the power of proteomics in precision diabetes medicine. Diabetologia. 2024. PMID: 38345659. doi:10.1007/s00125-024-06097-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。